Evidence map›Paper›PMID 26666915›Full record

ArticleAntimicrobial agents and chemotherapy2015

Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis.

Amy J Jones, Marcel Kaiser, Vicky M Avery

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Amy J JonesEskitis Institute for Drug Discovery, Griffith University, Nathan, Brisbane, Queensland, Australia a.jones@griffith.edu.au.
Marcel KaiserSwiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland.
Vicky M AveryEskitis Institute for Drug Discovery, Griffith University, Nathan, Brisbane, Queensland, Australia.
Griffith University · AUUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The screening of a focused library identified FTY720 (Fingolimod; Gilenya) as a potent selective antitrypanosomal compound active against Trypanosoma brucei gambiense and T. brucei rhodesiense, the causative agents of human African trypanosomiasis (HAT). This is the first report of trypanocidal activity for FTY720, an oral drug registered for the treatment of relapsing multiple sclerosis, and the characterization of sphingolipids as a potential new class of compounds for HAT.

Indexed as

Cell LineFingolimod HydrochlorideHEK293 CellsHumansParasitic Sensitivity TestsTrypanocidal AgentsTrypanosoma brucei bruceiTrypanosoma brucei gambienseTrypanosoma brucei rhodesienseTrypanosomiasis, AfricanFingolimod HydrochlorideTrypanocidal Agents

Identifiers

PMID26666915
PMCPMC4775930
OpenAlexW2220189981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.